Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118363
Title Alternative
Vedolizumab for pediatric IBD
Author
Fukura, Shoko Tokushima Prefectural Central Hospital
Takei, Mikiko Tokushima Prefectural Central Hospital|Tokushima Municipal Hospital
Takeuchi, Shunsuke Tokushima Prefectural Central Hospital
Tayama, Takahiro Tokushima Prefectural Central Hospital
Ono, Akemi Tokushima Prefectural Central Hospital
Ichihara, Yuko Tokushima Prefectural Central Hospital
Shichijo, Koichi Tokushima Prefectural Central Hospital
Suzuki, Yasuhiro Tokushima Prefectural Central Hospital
Mori, Kazuhiro Tokushima Prefectural Central Hospital
Kondo, Shuji Tokushima Prefectural Central Hospital KAKEN Search Researchers
Keywords
Ulcerative colitis
Inflammatory bowel disease
Vedolizumab
Infliximab
Pediatric IBD
Content Type
Journal Article
Description
Pediatric ulcerative colitis is likely to be more severe than adult ulcerative colitis. Failure to thrive should be considered during therapy. A 10-year-old boy was diagnosed with ulcerative colitis based on his clinical presentation and colonoscopy and biopsy results. The administration of 5-aminosalicylic acid and prednisolone resulted in remission ; however, the symptoms reappeared after the discontinuation of prednisolone. Then, infliximab was administered ; however, the patient was resistant to it and appeared to be dependent on prednisolone. Vedolizumab, a monoclonal antibody against α4β7 integrin, was administered, which resulted in rapid remission. A steady decrease in prednisolone followed, and remission was maintained even after prednisolone discontinuation. Vedolizumab may be effective in pediatric patients with moderate-to-severe refractory ulcerative colitis. Vedolizumab prevents lymphocytes from binding to MAdCAM-1, which is selectively expressed in the gastrointestinal submucosa, leading to the mitigation of the systemic side effects of immunosuppression, such as infections. In Japan, vedolizumab use is not yet approved for use in children, but its effectiveness and safety in children is expected to be investigated in the future.
Journal Title
The Journal of Medical Investigation
ISSN
13496867
13431420
NCID
AA11166929
Publisher
Tokushima University Faculty of Medicine
Volume
70
Issue
1-2
Start Page
294
End Page
297
Sort Key
294
Published Date
2023-02
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
University Hospital
Medical Sciences